Skip to main content
SpringerLink
Log in

How Should Long-Term Safety of a New Antiarrhythmic Drug Be Determined?

  • Chapter
The Evaluation of New Antiarrhythmic Drugs

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 11))

  • 36 Accesses

Abstract

During previous portions of this symposium, much useful information has been presented regarding the electrophysiology of ischemia and of antiarrhythmic drugs. One might characterize what is known about the “electrophysiology” of postmarketing drug surveillance as follows: it is fragmented, abberant and ectopic. A recent report of a United States Senate Committee advocating improved postmarketing drug surveillance echoes similar pleas from the past.1,2

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Culliton BJ and Waterfall WK. Post-marketing surveillance. Br Med J 280: 1175–6, 1980.

    Article  PubMed  CAS  Google Scholar 

  2. Wilson AB. Post-marketing surveillance of adverse reactions to new medicines. Br Med J 2: 1001–3, 1977.

    Article  PubMed  CAS  Google Scholar 

  3. Crawford MH, Karliner JS and O’Rourke RA. Favorable effects of oral maintenance digoxin therapy on left ventricular performance in normal subjects: echocardiographic study. Am J Cardiol 38: 843–7, 1976.

    Article  PubMed  CAS  Google Scholar 

  4. Ryan WF and Karliner JS. Effects of tocainide on left ventricular performance at rest and during alterations in heart rate and systemic arterial pressure: an echocardiographic study. Br Heart J 41: 175-81, 1979.

    Article  PubMed  CAS  Google Scholar 

  5. Remington RD. Post-marketing drug surveillance: a comparison of methods. Am J Pharm 150: 72–80, 1978.

    PubMed  CAS  Google Scholar 

  6. Melmon KL and Morelli HF. Drug reactions. In: Melmon KL and Morelli HF, ed. Clinical Pharmacology. Basic Principles in Therapeutics. 2nd ed. New York: Macmillan, 1978: 977.

    Google Scholar 

Download references

Authors
  1. Joel S. Karliner M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Lankenau Hospital, Philadelphia, Pennsylvania, USA

    Joel Morganroth M.D. , Leonard S. Dreifus M.D.  & Eric L. Michelson M.D. ,  & 

  2. School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

    E. Neil Moore D.V.M., Ph. D.

Rights and permissions

Reprints and permissions

Copyright information

© 1981 Martinus Nijhojf Publishers bv, The Hague.

About this chapter

Cite this chapter

Karliner, J.S. (1981). How Should Long-Term Safety of a New Antiarrhythmic Drug Be Determined?. In: Morganroth, J., Moore, E.N., Dreifus, L.S., Michelson, E.L. (eds) The Evaluation of New Antiarrhythmic Drugs. Developments in Cardiovascular Medicine, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-8270-3_21

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-8270-3_21

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-009-8272-7

  • Online ISBN: 978-94-009-8270-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation